Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04688567
Other study ID # Dnr: 2019-03786
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 1, 2019
Est. completion date March 30, 2021

Study information

Verified date April 2023
Source Vastra Gotaland Region
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The effect of iCBT for adults with anxiety disorders is well-known. However, drop-out rates are common. In recent years more focus has been directed to the importance of patients being active agents in their own care and to increase the patient´s involvement in health care. Studies show that involving patients´ in treatment decisions and management of their own health care can contribute to better treatment outcomes and more appropriate use of health care service. Few studies have evaluated patient involvement in iCBT-treatment. This study aims to evaluate the effect of patient-driven iCBT-treatment for patients with anxiety disorders seeking primary care in a randomized controlled trial. The study investigates the effect of patient-driven iCBT treatment of perceptions of being able to control the treatment and on drop-out from treatment. In addition, secondary research questions investigate measures of empowerment, anxiety and depression symptoms, general disability, satisfaction with treatment and feelings of being able to cope with one's mental illness in patient-driven iCBT.


Description:

The following research questions will be examined: Primary research questions: 1. Is there a difference between participants in patient-driven digital psychological treatment, compared to standardized internet CBT, in perceptions of how much they've been able to control their treatment (measured with a questionnaire developed by the researchers for this study)? 2. What is the effect of patient-driven digital psychological treatment, compared to standardized internet CBT, on frequency of completers and completed modules among adults with anxiety disorders? Secondary research questions: 3. What is the effect of patient-driven digital psychological treatment, compared to standardized internet CBT, on the experience of empowerment, (measured by the "Empowerment Scale"), for adults with anxiety disorders? 4. What is the effect of patient-driven digital psychological treatment, compared to standardized internet CBT, on anxiety (measured with GAD-7), depression (measured with MADRS-S), general disability (measured with WHODAS 2.0) and steps in "valued direction" (measured with "Bull´s Eye compass") for adults with anxiety disorders? Associations: 5. Is there a correlation between perceptions of how much one has been able to control the treatment (measured with a questionnaire developed by the researchers for this study), feelings of being able to cope with one's mental illness (measured with Patient Enablement Instrument), how satisfied participants are with their treatment (measured vid CSQ-8), perceptions of empowerment (measured with the "Empowerment Scale") and changes in anxiety symptoms (measured with GAD-7)? 6. Does perceptions of how much participants have been affected by the pandemic of Covid-19 in their daily life correlate with anxiety symptoms (measured with GAD-7) 3 months after termination of treatment? Mediation: 7. What is the mediating effect of empowerment, measured by the "Empowerment Scale", on changes in anxiety symptoms (measured with GAD-7)?


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date March 30, 2021
Est. primary completion date March 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Has reached the age of 18 - Has access to a computer with internet connection - Speak and understand Swedish - Meets the diagnostic criteria for an anxiety disorder (social anxiety, GAD (Generalized Anxiety Disorder), panic disorder, obsessive-compulsive disorder or unspecified anxiety disorder) Exclusion Criteria: - has started medication for mental illness or made major changes regarding the medication during the past 4 weeks - has serious suicidal thoughts or suicidal plans - has complex comorbidity or is in need of other care for mental illness in addition to iCBT - is receiving other psychological treatment during the treatment period

Study Design


Intervention

Behavioral:
Patient-driven iCBT
1) Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment by the time of the randomization call. The participant can choose which of the available treatment programs (targeting anxiety, worry, stress, sleep disorders or depression) they want to undergo, how many modules in the treatment program they want to complete and in what order, for how many weeks they want to complete the treatment as well as how much telephone contact and how much written contact they want to have with their therapist.
Standardized iCBT (TAU)
2) Patients who are randomized to the control condition (standardized iCBT) undergo the usual iCBT program available for anxiety disorders for 8 weeks. The psychologist provide weekly feedback on the patient's exercises and interact with the patient via secure encrypted messages in the treatment program. A follow-up telephone call takes place at the middle of treatment and at the end of the treatment.

Locations

Country Name City State
Sweden Department of Psychology, University of Gothenburg Gothenburg

Sponsors (1)

Lead Sponsor Collaborator
Vastra Gotaland Region

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Questions of perceptions in how much one has been able to control the treatment Perceptions in how much one has been able to control the treatment is measured by a questionnaire developed by the researchers for this study. The questionnaire consists of 9 items and each item is answered on a seven-point scale, from "Not at all" to "To a large extent". At the end of treatment (after 8-16 weeks depending on treatment condition)
Primary Adherence to treatment Adherence to treatment is measured by counting number of completed modules in the treatment program for each participant At the end of treatment (after 8-16 weeks depending on treatment condition)
Secondary Changes in feelings of empowerment Empowerment is measured with the Empowerment Scale (Rogers, Chamberlin, Ellison & Crean, 1997). The scale consists of 28 items which are answered on a four-point likert scale. Score ranges between 28 and 112. Higher scores indicates that the person feels more empowered. Baseline (Pre-treatment), Middle of treatment, At the end of treatment (after 8-16 weeks depending on treatment condition) and by 3 months follow up
Secondary Perceptions of being able to cope with one's mental illness Perceptions of being able to cope with one's mental illness is measured with the Patient Enablement Instrument (PEI; Howie, Heaney & Maxwell, 1997). The instrument consists of 6 items and are graded on a three-point scale. Score ranges between 0-12, with higher score indicating higher patient enablement. At the end of treatment (after 8-16 weeks depending on treatment condition) and by 3 months follow up
Secondary Satisfaction with treatment Satisfaction with treatment is measured by The Client Satisfaction Questionnaire- 8 item version (CSQ-8; Attkisson & Greenfield, 1998). The questionnaire consists of 8 items and are graded on a four-point scale. Scores ranges from 8-32, with higher scores indicating higher satisfaction. At the end of treatment (after 8-16 weeks depending on treatment condition) and by 3 months follow up
Secondary Changes in Anxiety symptoms Anxiety is measured with the GAD-7 instrument (Generalized Anxiety Disorder 7 item scale). The scale consists of 7 items. The score ranges from 0 to 21, with higher scores indicating more anxiety symptoms. There are thresholds for mild, medium and severe anxiety (Spitzer, Kroenke, Williams & Löwe 2006). Baseline (Pre-treatment), Middle of treatment, At the end of treatment (after 8-16 weeks depending on treatment condition) and by 3 months follow up
Secondary Changes in Depressive symptoms Symptoms of depression is measured with Madrs-s (Montgomery Åsberg Depression Rating Scale; Montgomery & Åsberg, 1979). The instrument consists of 9 items. Scores ranges from 0 to 60, with higher scores indicating more depressive symptoms. There are cut-off points for symptom severity. Baseline (Pre-treatment), middle of treatment, At the end of treatment (after 8-16 weeks depending on the treatment condition) and by 3 months follow up
Secondary Changes in General disabillity General disability is measured with the 12-item version of the generic assessment tool WHO Disability Assessment Schedule (WHODAS 2.0; Rhem, Ustun, Saxena, Nelson, Chatterji, Ivis & Adlaf, 1999). Scores range from 12-60, with a higher score indicating higher disability. The instrument has established normative data. Baseline (Pre-treatment), Middle of treatment, At the end of treatment (after 8-16 weeks depending on treatment condition) and by 3 months follow up
Secondary Changes in steps towards "valued direction" Steps towards "valued direction" is measured with "the Bull´s Eye Values Survey" (Lundgren, Louma, Dahl, Strohsal & Melin, 2012). Baseline (Pre-treatment), Middle of treatment, At the end of treatment (after 8-16 weeks depending on treatment condition) and by 3 months follow up
Secondary 10. Questions about how much one has been affected by the pandemic of Covid-19 Perceptions about how much one has been affected by the pandemic of Covid-19 is measured by a questionnaire developed by the researchers for this study. The questionnaire consists of 7 items that is answered on a seven-point scale. 1 indicating= To a very large extent for the worse; 4= not at all / not relevant; 7= to a very large extent for the better. By 3 months follow up
See also
  Status Clinical Trial Phase
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Recruiting NCT06019429 - Promoting Social-emotional Development and Self-esteem in Primary School Students N/A
Completed NCT05252026 - Indicated Prevention Transdiagnostic Intervention for Adolescents At High Risk of Emotional Problems N/A
Completed NCT04851366 - Selective Prevention Transdiagnostic Intervention for At-risk Adolescents N/A
Not yet recruiting NCT05061225 - The Efficacy of a Physical Activity Counselling Intervention on Mental Health in Firefighters N/A
Recruiting NCT05510921 - Evaluation of the Minimalist Music and Birdsongs in the Anxiety of Nursing Professionals in Oncology N/A
Completed NCT05589090 - Super Skills for Life Effectiveness in the Online Modality N/A
Active, not recruiting NCT05889078 - The Effects of Walking in Nature (vs. an Urban Setting) on the Wellbeing of Postsecondary Students. N/A
Completed NCT04060940 - Emotion Regulation Therapy for Clinical Worry and Rumination N/A
Recruiting NCT06356090 - SPACE: a Parent-based Treatment for Pediatric OCD N/A
Recruiting NCT06148454 - Study of Positive Psychology and Effects on Well-being of Anaesthesiologists in Hong Kong N/A
Completed NCT04562948 - Community Applications of the MindShift App
Completed NCT03437317 - Emotional Perceptual Training as a Treatment for Social Anxiety: Behavioral and Neural Evidence. N/A
Not yet recruiting NCT06404788 - Anxiety Level Among Patients With Chronic Low Back Pain
Not yet recruiting NCT04902313 - Cultivating Resilience in Oncology Practice N/A
Recruiting NCT04847076 - Feasibility of M-health Version of "What Were We Thinking" Intervention to Promote Maternal Postpartum Mental Health N/A
Not yet recruiting NCT05821634 - Digital Phenotyping of Anxiety and Anxiety-Related Alcohol Co-occurrence: Pilot Study N/A
Completed NCT05482724 - Super Skills for Life Effectiveness in Clinical Settings N/A
Active, not recruiting NCT04945239 - Amplification of Positivity to Enhance Social Connections in Anxiety and Depression N/A
Completed NCT05296057 - Pilot to Evaluate VR-Therapy on People With Epilepsy and Related Anxiety N/A